- Stocks
- Pharma & Healthcare
- Aarti Pharmalabs
Aarti Pharmalabs share price
NSE: AARTIPHARMPharma & HealthcareDrug Manufacturers - Specialty & Generic
Aarti Pharmalabs at a glance
Aarti Pharmalabs (NSE: AARTIPHARM) closed at ₹835.00 on 19 Oct 2026, down 4.78% on the day. With a market capitalisation of ₹7,572 Cr, it ranks 641st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 43.4× trailing earnings, against a return on equity of 13.7% in FY25. Over the past year the share price has risen 0.3%. Its 52-week range is ₹585.00 (30 Mar 2026) to ₹1,002.40 (30 Sep 2026); the last close is 16.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹583 Cr (+3.3% year on year) and net profit ₹56 Cr (−37.1%), on a consolidated basis. Promoters held 42.86% of the company as of 30 Jun 2026; 11.08% of promoter shares were pledged.
Key numbers
- Market cap
- ₹7,572 CrRank 641 on NSE
- P/E (trailing)
- 43.4×
- Price to book
- 3.41×FY25
- EPS (TTM)
- ₹20.57to Q4 FY26
- ROE
- 13.7%FY25
- ROCE
- 17.2%FY25
- Debt to equity
- 0.2FY25
- Net profit margin
- 12.9%FY25
- Book value / share
- ₹219.55FY25
- Dividend payout
- 11.6%FY25
- 52-week high
- ₹1,002.4030 Sep 2026
- 52-week low
- ₹585.0030 Mar 2026
- 1-year return
- +0.3%
- RSI (14-day)
- 42.4
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −4.78% | −4.2% | +0.7% | +19.3% | +0.3% |
Aarti Pharmalabs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹555 Cr | ₹458 Cr | ₹538 Cr | ₹564 Cr | ₹386 Cr | ₹418 Cr | ₹432 Cr | ₹583 Cr |
| Revenue YoY | +21.2% | +4.1% | +19.9% | +11.5% | −30.5% | −8.7% | −19.6% | +3.3% |
| Net profit | ₹55 Cr | ₹55 Cr | ₹74 Cr | ₹88 Cr | ₹51 Cr | ₹29 Cr | ₹43 Cr | ₹56 Cr |
| Net profit YoY | +17.8% | +5.4% | +40.2% | +35.4% | −7.5% | −47.7% | −41.8% | −37.1% |
| Net margin | 10.0% | 11.9% | 13.8% | 15.7% | 13.3% | 6.8% | 10.0% | 9.5% |
| EPS | ₹6.12 | ₹6.03 | ₹8.16 | ₹9.75 | ₹5.46 | ₹3.08 | ₹5.29 | ₹6.74 |
Aarti Pharmalabs financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹1,200 Cr | ₹1,945 Cr | ₹1,853 Cr | ₹2,115 Cr |
| Operating profit | ₹155 Cr | ₹261 Cr | ₹300 Cr | ₹361 Cr |
| Net profit | ₹122 Cr | ₹193 Cr | ₹217 Cr | ₹272 Cr |
| EPS (₹) | ₹13.00 | ₹21.00 | ₹24.00 | ₹30.00 |
| Cash from operations | −₹44 Cr | ₹263 Cr | ₹216 Cr | ₹332 Cr |
| Total debt | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹104 Cr |
| Shareholders' equity | ₹1,386 Cr | ₹1,558 Cr | ₹1,757 Cr | ₹1,990 Cr |
Aarti Pharmalabs shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 44.29% | 43.72% | 42.88% | 43.10% | 43.08% | 42.86% |
| Foreign institutions | 7.36% | 7.35% | 8.02% | 7.68% | 8.39% | 8.17% |
| Domestic institutions | 7.53% | 7.79% | 6.96% | 7.66% | 7.41% | 7.22% |
| Non-institutions | 40.81% | 41.12% | 42.13% | 41.54% | 41.11% | 41.74% |
| Promoter shares pledged | — | 0.01% | 0.01% | 0.01% | 11.03% | 11.08% |
Aarti Pharmalabs vs peers
The listed Pharma & Healthcare companies nearest to Aarti Pharmalabs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| HCGHealthcare Global Enterprises | ₹570.00 | −3.39% | −16.4% | ₹8,510 Cr | — | — |
| SUVENSuven Life Sciences | ₹290.50 | −4.71% | +39.0% | ₹8,208 Cr | — | — |
| SANOFICONRSanofi Consumer Healthcare India | ₹3,473.40 | −2.39% | −25.8% | ₹7,999 Cr | 31 | — |
| AARTIPHARMAarti Pharmalabs | ₹835.00 | −4.78% | +0.3% | ₹7,572 Cr | 43.4 | — |
| THYROCAREThyrocare Technologies | ₹469.95 | −3.12% | +11.1% | ₹7,480 Cr | 46.1 | — |
| SUPRIYASupriya Lifescience | ₹872.50 | −1.55% | +20.7% | ₹7,022 Cr | 33.6 | — |
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
Ask anything about Aarti Pharmalabs
Pivot answers on the live chart with evidence you can check, and tests strategies against AARTIPHARM's own history. Try: “Why has AARTIPHARM moved over the last three months?” · “Backtest a 50-day moving-average crossover on AARTIPHARM over five years” · “Compare AARTIPHARM with HCG on margins and valuation”
Frequently asked questions about Aarti Pharmalabs
What is the share price of Aarti Pharmalabs today?
Aarti Pharmalabs (NSE: AARTIPHARM) last closed at ₹835.00 on 19 Oct 2026. Its 52-week high is ₹1,002.40 and its 52-week low is ₹585.00.
What is the market cap of Aarti Pharmalabs?
Aarti Pharmalabs' market capitalisation is ₹7,572 Cr (₹7,572 Cr) at the 19 Oct 2026 close, ranking 641st among the NSE companies Pivot tracks.
What is the P/E ratio of Aarti Pharmalabs?
Aarti Pharmalabs trades at a trailing P/E of 43.4. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 46.1.
What is the ROE and ROCE of Aarti Pharmalabs?
Return on equity was 13.7% in FY25 and return on capital employed was 17.2% in FY25 (consolidated figures).
Is Aarti Pharmalabs a debt-free company?
No. Aarti Pharmalabs' debt-to-equity ratio was 0.2 in FY25, with total debt of ₹104 Cr.
What were Aarti Pharmalabs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Aarti Pharmalabs reported revenue of ₹583 Cr, +3.3% year on year, and net profit of ₹56 Cr, −37.1% year on year.
How has Aarti Pharmalabs stock performed over the last year?
Aarti Pharmalabs' share price has risen 0.3% over the past year, +19.3% over three months and +0.7% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Aarti Pharmalabs?
As of 30 Jun 2026: promoters 42.86%, foreign institutions 8.17%, domestic institutions 7.22%, non-institutions 41.74%. 11.08% of promoter shares were pledged.
Who are Aarti Pharmalabs' competitors?
The listed Pharma & Healthcare companies closest to Aarti Pharmalabs by market cap are Healthcare Global Enterprises, Suven Life Sciences, Sanofi Consumer Healthcare India, Thyrocare Technologies, Supriya Lifescience and Morepen Laboratories.
Is Aarti Pharmalabs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aarti Pharmalabs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AARTIPHARM against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text